Abstract: Disclosed are compounds of Formula (I): and salts thereof. Also, disclosed are methods of using the compounds in the treatment of proliferative diseases, such as cancer, and to pharmaceutical compositions comprising at least one compound of Formula (I) or a pharmaceutically acceptable salt.
Abstract: Compounds are provided which are phosphonate and phosphinate activators and thus are useful in treating diabetes and related diseases and have the structure wherein is a heteroaryl ring; R4 is —(CH2)n—Z—(CH2)m—PO(OR7)(OR8), —(CH2)nZ—(CH2)m—OPO(OR7)R9, —(CH2)nZ—(CH2)m—OPO(R9)(R10), or —(CH2)nZ—(CH2)m—PO(R9)(R10); R5 and R6 are independently selected from hydrogen, alkyl and halogen; Y is R7(CH2)s or is absent; and X, n, Z, m, R4, R5, R6, R7, and s are as defined herein; or a pharmaceutically acceptable salt thereof. A method for treating diabetes and related diseases employing the above compounds is also provided.
Type:
Grant
Filed:
January 24, 2011
Date of Patent:
April 10, 2012
Assignee:
Bristol-Myers Squibb Company
Inventors:
Denis E. Ryono, Peter T. W. Cheng, Scott A. Bolton, Sean Chen, Yan Shi, Wei Meng, Joseph A. Tino, Richard B. Sulsky
Abstract: Disclosed are compounds of Formula (I): and salts thereof. Also, disclosed are methods of using the compounds in the treatment of proliferative diseases, such as cancer, and to pharmaceutical compositions comprising at least one compound of Formula (I) or a pharmaceutically acceptable salt.
Abstract: Disclosed are fused heterocyclic compounds of Formula (I) or pharmaceutically-acceptable salts or stereoisomers thereof. Also disclosed are methods of using such compounds in the treatment of at least one androgen receptor-associated condition, such as, for example, cancer, and pharmaceutical compositions comprising such compounds.
Type:
Grant
Filed:
June 26, 2008
Date of Patent:
November 29, 2011
Assignee:
Bristol-Myers Squibb Company
Inventors:
Derek J. Norris, Ashvinikumar V. Gavai, James Aaron Balog, Joel F. Austin, Weifang Shan, Yufen Zhao, Andrew James Nation, Wen-Ching Han
Abstract: The invention is directed to pyridinone compounds useful for modulating Met kinase, having the following structure: and is further directed to pharmaceutical compositions comprising the compound; and methods for treating proliferative diseases, such as cancer by the administration of this compound.
Type:
Grant
Filed:
November 8, 2007
Date of Patent:
December 14, 2010
Assignee:
Bristol-Myers Squibb Company
Inventors:
Robert M. Borzilleri, Gretchen M. Schroeder, Zhen-Wei Cai
Abstract: The present invention is directed to compounds having the formula (I), and/or pharmaceutically-acceptable salts thereof, useful in the treatment of androgen-receptor associated conditions, wherein Ar is aryl, substituted aryl, heteroaryl, or substituted heteroaryl; L is a linker as defined in the specification; R1 may be hydrogen, cyano, alkyl, substituted alkyl, aryl, substituted aryl, cycloalkyl, substituted cycloalkyl, heterocyclo, substituted heterocyclo, heteroaryl, or substituted heteroaryl, as defined in the specification; R2 is hydrogen, lower alkyl, or substituted lower alkyl; and R3, R4 and R5 are optionally non-interfering substituents as defined in the specification.
Type:
Grant
Filed:
October 12, 2006
Date of Patent:
August 17, 2010
Assignee:
Bristol-Myers Squibb Company
Inventors:
James Aaron Balog, Mark E. Salvati, Brian E. Fink
Abstract: This invention relates to novel lactams having the formula (I): to their pharmaceutical compositions and to their methods of use. These novel compounds inhibit the processing of amyloid precursor protein and, more specifically, inhibit the production of A?-peptide, thereby acting to prevent the formation of neurological deposits of amyloid protein. More particularly, the present invention relates to the treatment of neurological disorders related to ?-amyloid production such as Alzheimer's disease and Down's Syndrome.
Abstract: Fused cyclic compounds, methods of using such compounds in the treatment of nuclear hormone receptor-associated conditions such as cancer and immune disorders, and pharmaceutical compositions containing such compounds.
Type:
Grant
Filed:
March 20, 2006
Date of Patent:
February 2, 2010
Assignee:
Bristol-Myers Squibb Company
Inventors:
Mark E. Salvati, James Aaron Balog, Dacia A. Pickering, Sören Giese, Aberra Fura, Wenying Li, Ramesh N. Patel, Ronald L. Hanson, Toomas Mitt, Jacques Y. Roberge, James R. Corte, Steven H. Spergel, Richard A. Rampulla, Raj N. Misra, Hai-Yun Xiao
Abstract: Disclosed are anthranilic acid derivatives having Formula (I): and pharmaceutically acceptable salts thereof; and pharmaceutical compositions comprising such compounds. Also disclosed are methods of using such compounds in the treatment of conditions or diseases such as prostate cancer, and methods of using such compounds in the inhibition of 17?-hydroxysteroid dehydrogenase type 3 enzyme.
Type:
Grant
Filed:
October 21, 2005
Date of Patent:
August 4, 2009
Assignee:
Britsol-Myers Squibb Company
Inventors:
Ellen K. Kick, R. Michael Lawrence, Brian E. Fink, Raj N. Misra, Gregory D. Vite
Abstract: Tricycloundecanes compounds, methods of using such compounds in the treatment of nuclear hormone receptor-associated conditions such as cancer and immune disorders, and pharmaceutical compositions containing such compounds are disclosed.
Type:
Grant
Filed:
October 17, 2006
Date of Patent:
June 23, 2009
Assignee:
Bristol-Myers Squibb Company
Inventors:
James Aaron Balog, David John Fairfax, Gregory Scott Martin, Mark E. Salvati, Hai-Yun Xiao
Abstract: The present invention is directed to compounds having the formula I or II: including salts thereof, and methods for using them for the treatment of cancer.
Type:
Grant
Filed:
September 28, 2006
Date of Patent:
June 16, 2009
Assignee:
Bristol-Myers Squibb Company
Inventors:
Robert M. Borzilleri, Xiao-Tao Chen, David K. Williams, John S. Tokarski, Robert F. Kaltenbach
Abstract: Fused cyclic compounds, methods of using such compounds in the treatment of nuclear hormone receptor-associated conditions such as cancer and immune disorders, and pharmaceutical compositions containing such compounds.
Type:
Grant
Filed:
July 7, 2005
Date of Patent:
April 14, 2009
Assignee:
Bristol-Myers Squibb Company
Inventors:
Mark E. Salvati, James Aaron Balog, Dacia A. Pickering, Sören Giese, Aberra Fura, Wenying Li, Ramesh N. Patel, Ronald L. Hanson, Toomas Mitt, Jacques Y. Roberge, James R. Corte, Steven H. Spergel, Richard A. Rampulla, Raj N. Misra, Hai-Yun Xiao
Abstract: The invention is directed to compounds having the following Formula I: and methods of using them for the treatment of proliferative diseases.
Type:
Grant
Filed:
April 19, 2006
Date of Patent:
December 30, 2008
Assignee:
Bristol-Myers Squibb Company
Inventors:
Robert M. Borzilleri, Gretchen M. Schroeder, Lyndon A. M. Cornelius
Abstract: Disclosed are fused cyclic compounds, method of using such compounds in the treatment of nuclear hormone receptor-associated conditions such as cancer and immune disorders, and pharmaceutical compositions containing such compounds of formula Also disclosed are fused heterocyclic imido and amido compounds of formula and stereoisomers thereof. The groups G, L, Z1, Z2, Q1, Q2, A1, A2, Y?, and W? are defined herein.
Abstract: Disclosed are sultam compounds of Formula (I) or a pharmaceutically-acceptable salt thereof. Also disclosed are methods of using such compounds in the treatment of at least one nuclear hormone receptor-associated condition, such as, for example, cancer and immune disorders, and at least one pharmaceutical composition comprising such compounds.
Type:
Grant
Filed:
September 5, 2007
Date of Patent:
December 23, 2008
Assignee:
Bristol-Myers Squibb Company
Inventors:
Weifang Shan, James Aaron Balog, Andrew James Nation, Ashvinikumar V. Gavai, Wen-Ching Han, Mark E. Salvati